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Abstract
Background
Placebo or sham controls are the standard against which the benefits and harms of many
active interventions are measured. Whilst the components and the method of their delivery
have been shown to affect study outcomes, placebo and sham controls are rarely reported
and often not matched to those of the active comparator. This can influence how beneficial
or harmful the active intervention appears to be. Without adequate descriptions of placebo
or sham controls, it is difficult to interpret results about the benefits and harms of active inter-
ventions within placebo-controlled trials. To overcome this problem, we developed a check-
list and guide for reporting placebo or sham interventions.
Methods and findings
We developed an initial list of items for the checklist by surveying experts in placebo
research (n = 14). Because of the diverse contexts in which placebo or sham treatments are
used in clinical research, we consulted experts in trials of drugs, surgery, physiotherapy,
acupuncture, and psychological interventions. We then used a multistage online Delphi pro-
cess with 53 participants to determine which items were deemed to be essential. We next
convened a group of experts and stakeholders (n = 16). Our main output was a modification
of the existing Template for Intervention Description and Replication (TIDieR) checklist; this
allows the key features of both active interventions and placebo or sham controls to be con-
cisely summarised by researchers. The main differences between TIDieR-Placebo and the
original TIDieR are the explicit requirement to describe the setting (i.e., features of the physi-
cal environment that go beyond geographic location), the need to report whether blinding
was successful (when this was measured), and the need to present the description of pla-
cebo components alongside those of the active comparator.
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Conclusions
We encourage TIDieR-Placebo to be used alongside TIDieR to assist the reporting of pla-
cebo or sham components and the trials in which they are used.
Background
Placebo or sham controls are the standard against which the effectiveness of many active inter-
ventions are compared [1]. To appraise whether an active intervention is effective therefore
requires that the placebo or sham intervention be described. However, a decade of research
shows that placebo or sham interventions in trials are rarely reported in adequate detail. A
2010 systematic review found that between 8.2% (pharmacological) and 26.7% (nonpharmaco-
logical) trials adequately described placebo or sham interventions [2]. Ten years later, things
have barely improved [3]. Hence, the need to look more closely at what placebo or sham com-
parators are is becoming more widely recognised [4].
A possible reason for the failure to describe placebo or sham components is the misconcep-
tion that they are inactive or inert [5]. There would be little point in describing inert things. In
fact, placebos and sham interventions are a heterogeneous group of interventions that can
cause benefits and harms. Even simple lactose pills are active for diabetics or people with lac-
tose intolerance. The size, shape, and colour of drugs can influence the effects that are mea-
sured or perceived [6, 7]. In certain cultural contexts [8], for example, red tablets can produce
a larger stimulating effect than blue ones [9], expensive tablets may have greater analgesic
effects than generic cheap ones [10], and two placebos can be more effective than one [11].
More invasive placebo or sham interventions have greater effects [6, 7, 11]. Brand-name,
expensive interventions (or those believed to be expensive and have a brand name) have been
shown in some studies to have greater effects [12, 13]. In one study, cellulose acetate phthalate
(typically used to coat pills) was reported to have activity against several sexually transmitted
diseases, including herpes, in mice [14]. See S1 Text for additional examples.
Placebo interventions can also cause adverse events. For instance, some placebo pills delib-
erately contain ingredients to mimic a drug side effect to improve blinding [15]. For instance,
in some trials of oseltamivir, the placebo contained dehydrocholic acid and dibasic calcium
phosphate dihydrate. This was presumably done to mimic the bitter taste of the active inter-
vention (oseltamivir powder) and maintain blinding. However, dehydrocholic acid can cause
gastrointestinal symptoms [16]. This may have led to underestimating the gastrointestinal
adverse events of oseltamivir, which was determined by comparing rates of gastrointestinal
adverse events in drug with placebo groups. The term ‘active’ is used to qualify ‘placebo’ when
the placebo contains an ingredient that mimics the side effect of the drug. To reduce concep-
tual ambiguity, we preserve the term ‘active’ to refer to nonplacebo interventions.
If placebo or sham interventions were always matched with their active comparator inter-
ventions, the problem with failure to describe placebo or sham interventions would not be as
serious. This is because a trial comparing the suitably matched placebo or sham with an active
intervention would reveal the incremental benefit and harm (if any) of the relevant compo-
nents of the active intervention. However, a 2016 study found that 44% of control treatments
were inadequately matched [17]. Worse, since placebo components are not well reported, we
cannot determine precisely how common unmatching is. Without clear reporting, researchers
and clinical decision-makers will not know what the effects of the placebo or sham comparator
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are and could subsequently overestimate or underestimate the benefits or harms of the active
intervention they are testing.
The Consolidated Standards of Reporting Trials (CONSORT) statement recommends that
trial interventions be adequately described. However, little detail is provided, and subsequent
researchers have found that intervention reporting was poor [18]. To address intervention
reporting, the Template for Intervention Description and Replication (TIDieR) checklist was
developed to aid reporting of interventions and can be used in conjunction with CONSORT.
However, neither CONSORT nor TIDieR explicitly mention placebo or sham controls, and
our background research revealed that they require some modification to guide adequate
reporting of these interventions [3].
To address this gap, a team of researchers, editors, and patient representatives developed
TIDieR-Placebo. It modifies the original TIDieR so that it is directly applicable to placebo and
sham interventions and is designed to be used alongside the original TIDieR. Some of these
individuals were also involved in developing the original TIDieR.
Methodology
We followed Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Net-
work guidance for developing this reporting guideline. The development of TIDieR-Placebo
consisted of 5 main phases: (1) background research, (2) panel selection, (3) generation of ini-
tial checklist, (4) optimisation of the checklist, and (5) approval of the final checklist.
Preliminary research
JH, TH, and RKW conducted preliminary research exploring the need to describe placebo and
sham components adequately [2, 3, 19]. JH drafted and registered the protocol [20].
Panel selection
To advise on the development of the checklist, we invited panel members who were identified
based on a review of key authors in the field, as well as membership in the Society for Interdis-
ciplinary Placebo Studies (SIPS). We ensured that researchers with the relevant expertise in
different types of placebo or sham controls (physiotherapy, surgery acupuncture, drug), or
reporting guidelines were invited. One of the panel members (AP) obtained ongoing feedback
from 5 patient representatives throughout the guideline development process (see S1 Data for
details).
Generation of the initial checklist
The panel generated the initial list of items, including illustrative vignettes, through brain-
storming and discussion and taking into account existing TIDieR items [21].
Optimisation of the checklist
S2 Text has full details of the optimisation process.
Delphi survey. Members of the SIPS, together with an additional 24 people with expertise
in placebo/sham controls or research reporting, were invited to take part in a multistage Del-
phi survey process. They were asked to rate items on the long list from 1 (omit) to 4 (essential)
and were given the opportunity to provide full-text comments and recommend additional
items. For subsequent rounds, participants were asked to rate the items generated in the long
list and again had the opportunity to provide free-text comments. We planned on having 2 or
3 rounds depending on the level of agreement reached.
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Consensus meeting and approval of final checklist. The results of the Delphi survey
were reported at a 2-day consensus meeting with the panel members (supplemented by addi-
tional guideline reporting experts) on 10–11 September 2019, in Oxford, UK. Meeting attend-
ees discussed the results of the Delphi survey and agreed on the final list of items.
To reduce the burden of ‘guideline fatigue’, the panel agreed to be conservative in choices
to deviate from existing related checklists (especially TIDieR and CONSORT). For similar rea-
sons, we decided that the extension should be concise and machine-readable. We also agreed
that items that were highly ranked by Delphi survey respondents should be kept. Disagree-
ments were resolved by discussion.
Deviations from protocol
In the protocol, we anticipated having 12 members of the panel [20], and the final number was
14.
Results
TIDieR-Placebo panel
Fifteen individuals were invited to be part of the TIDieR-Placebo panel, and 14 agreed. Nine
were female, and 5 were male; 9 were based in the United Kingdom, 2 in the United States, 2
in Continental Europe, and 1 in Australia.
Generation of initial checklist
This resulted in a long list of 45 placebo or sham components for potential inclusion. There
were 14 generic items (which included all the original TIDieR items) and other items useful
only for specific types of sham interventions (such as ‘participant access to operation note
detailing sham surgery’).
Optimisation of the checklist
Delphi survey. For the first round of our web-based survey, we invited 172 participants,
and 31% (n = 53) responded (see Table 1 for characteristics). Of the 45 items, 31 were ranked
as essential or desirable by at least 85% of respondents, 14 were moderately ranked as essential
or desirable by at least 65% of respondents, and 4 additional items were suggested in the free-
text comments (S2 Text presents full details). For round 2, only those who responded to round
1 (n = 53) were invited to take part. Sixty-six percent (35 of 53) responded. After 2 rounds, 36
items were included in the draft checklist.
Consensus meeting. Following the Delphi survey respondents, the placebo expert panel
agreed that the original TIDieR items should be kept but that TIDieR-Placebo required 2 addi-
tions and several elaborations in order to be applicable to placebo or sham controls.
The 2 items most consistently ranked as ‘essential’ by >80% of Delphi respondents were
reporting how placebo/sham components compared to those of the active intervention and
measuring the success of blinding. To achieve the former, we recommend that descriptions of
placebo or sham interventions are presented in a table alongside the active intervention’s
description. S1 Table is a checklist that can be used to guide reporting of placebo and active
interventions, and S2 Table contains descriptions of active and placebo/sham drug, surgery,
psychology, acupuncture, and physiotherapy interventions.
The group discussed measuring the success of blinding extensively. Earlier versions of the
CONSORT Statements recommended it [22], and later editions did not [23]. Whilst there are
many cases in which lack of success of blinding does not indicate lower quality (for example,
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Table 1. Respondent characteristics.
Demographics n = 53 (n)
Country of residence
Europe 40
USA 7
Canada 1
Australia 1
New Zealand 1
Israel 1
Not answered 2
Profession (tick all that apply)
Academic 36
Psychologist 19
Physician 8
Physiotherapist 3
Acupuncturist 2
Psychotherapist 2
Journal editor 1
Areas of practice (tick all that apply)
Health and medical psychology 18
Clinical psychology 15
Psychosomatic medicine 12
Cognitive neuroscience 11
Primary care 8
Epidemiology 5
Anaesthesiology 4
Pain 4
Internal medicine 3
Psychiatry 3
Medical ethics and philosophy 3
Physiotherapy 3
Clinical trials 3
Rehabilitation 2
Surgery 2
Neurology 1
Behavioural neuroscience 1
Anthropology 1
Integrative medicine oncology 1
Wellbeing and healing 1
Chiropractic education 1
Number of years since award of doctoral degree
�10 years 27
10< and�20 years 13
20< and�30 years 6
>30 years 3
Not answered 4
https://doi.org/10.1371/journal.pmed.1003294.t001
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in medication cessation trials and most exercise trials), measuring the success of blinding often
indicates whether the placebo or sham functioned as intended [24]. Hence, knowing whether
blinding was successful can be useful. Methods for measuring the success of blinding have
been developed and are currently in use. They include Bang’s ‘blinding index’ (BI) [25] and
James’ BI [26]. Both ask patients to state whether they believed they received the experimental
active intervention. In light of these considerations and to remain faithful to the Delphi survey
responses, we agreed to add measuring the success of blinding as a TIDieR-Placebo item. We
added a caveat that a measure of the success of blinding (or indeed any of the other items) is
not to condemn researchers that have not done so but to encourage those who have measured
the fidelity of blinding to report it. We plan to provide an outline of the case for and against
measuring the success of blinding in a separate publication; see S3 Text for additional discus-
sion of this point.
The additional explanations required to describe placebo or sham controls are all below
and in S2 Table. There was an extensive discussion around whether to use the term ‘setting’
(which was recommended in the free-text comments by Delphi respondents but not used by
the original TIDieR). In the meeting, it was agreed by most attendees that setting as well as
location for item 7 (Where) can influence outcomes. Location is typically understood as geo-
graphic location, whereas setting can also include potentially important features of the loca-
tion, such as lighting and noise. Birth setting trials were the most markedly affected, with
between 68% and 85% of eligible women declining to be in trials because of preference for a
particular healthcare setting [27]. In some trials, less specialised and less costly home settings
are as effective as hospital settings, independently of geographic location [28, 29]. Studies have
also found that factors such as noise, daylight deprivation, and light intensity may increase
stress and pain level, as well as affect length of hospital stay [30–32]. Also, surgical patients
might be recruited from outpatient clinics, preadmission clinics, or research clinics. Each of
these settings comes with a different potential anxiety that affect the type of patient recruited
as well as preoperative scores, which in turn can affect surgical outcomes. None of them are
primarily related to geographic location [33].
An issue that arose at the consensus meeting, but not the Delphi survey, surrounded the
ambiguity around whether certain control interventions are shams or placebos. For example,
in one trial measuring methods to reduce stress amongst researchers of violence, researchers
allocated participants to either group debriefings or 3 leisure sessions consisting of uplifting
film viewings [34]. The film viewings were not described as sham interventions, and it is not
clear whether they functioned as placebo/sham controls because taking ‘time out’ to watch a
light-hearted film could, and indeed has been known to, change physiology [35]. Hence, in
these cases, we recommend reporting the control according to TIDieR-Placebo. The same
applies if the control is usual care or waiting list [36].
After the meeting, the report and checklist were distributed to the participants to ensure it
reflected all decisions made, and this explanatory document was generated. It was then tested
for face validity with 20 researchers who were conducting placebo or sham-controlled trials of
different types. As a result, minor modifications were made.
Final TIDieR-Placebo checklist
We have elaborated on items only when they require explanation over and above that already
provided in the original TIDieR statement (see Table 2; downloadable version: S1 Table).
1. Brief name: Provide the name or a phrase that describes the placebo/sham interven-
tion. Brand-name, expensive interventions have been shown in some studies to have greater
effects (see above). The name also enables easy identification of the placebo or sham
PLOS MEDICINE
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Table 2. TIDieR-Placebo checklist (to be used alongside TIDieR-Placebo guide).
Item Where Located Where Located
Primary paper
(page or
appendix
number)
Other
(details)
Primary paper
(page or
appendix
number)
Other
(details)
Active intervention Placebo/sham intervention
1 Brief Name
Provide the name or a phrase that describes the
intervention
Provide the name or a phrase that describes the
placebo/sham intervention
2 Why
Describe any rationale, theory, or goal of the
elements essential to the intervention
Describe any rationale, theory, or goal of the
elements essential to the placebo/sham
intervention�
3 What (materials)
Describe any physical or informational
materials used in the intervention, including
those provided to participants or used in
intervention delivery or in training of
intervention providers. Provide information on
where the materials can be accessed (such as
online appendix, URL)
Describe any physical or informational materials
used in the placebo/sham intervention, including
those provided to participants or used in
intervention delivery or in training of intervention
providers. Provide information on where the
materials can be accessed (such as an online
appendix, URL)
4 What (procedures)
Describe each of the procedures, activities, and/
or processes used in the intervention, including
any enabling or support activities
Describe each of the procedures, activities, and/or
processes used in the placebo/sham intervention,
including any enabling or support activities
5 Who provided
For each category of intervention provider
(such as psychologist, nursing assistant),
describe their expertise, background, and any
specific training given
For each category of placebo/sham intervention
provider (such as psychologist, nursing assistant),
describe their expertise, background, and any
specific training given
6 How
Describe the modes of delivery (such as face to
face or by some other mechanism, such as
internet or telephone) of the intervention and
whether it was provided individually or in a
group
Describe the modes of delivery (such as face to face
or by some other mechanism, such as internet or
telephone) of the placebo/sham intervention and
whether it was provided individually or in a group
7 Where
Describe the type(s) of location(s) where the
intervention occurred, including any necessary
infrastructure or relevant features
Describe the type(s) of locations(s) and settings
where the placebo/sham intervention occurred,
including any necessary infrastructure or relevant
features
8 When and how much
Describe the number of times the intervention
was delivered and over what period of time,
including the number of sessions, their
schedule, and their duration, intensity, or dose
Describe the number of times the placebo/sham
intervention was delivered and over what period of
time, including the number of sessions, their
schedule, and their duration, intensity, or dose. If
relevant, include the duration of the pre- and
postrandomisation consultations
9 Tailoring
If the intervention was planned to be
personalised, titrated, or adapted, then describe
what, why, when, and how
If the placebo/sham intervention was planned to be
personalised, titrated, or adapted, then describe
what, why, when, and how
10 Modifications
If the intervention was modified during the
course of the study, describe the changes (what,
why, when, and how)
If the placebo/sham intervention was modified
during the course of the study, describe the changes
(what, why, when, and how)
(Continued)
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intervention in the report. Abbreviations or acronyms should be explained in full or short
descriptive statements provided. Examples:
• ‘0.9% normal saline [37]’.
• ‘. . .the enhanced group’s active treatment was referred to as Singulair [38]’.
2. Why: Describe any rationale, theory, or goal of the elements essential to the placebo/
sham intervention. The rationale for the placebo or sham chosen will usually (but not always)
be to control for certain components of the active intervention. These components should be
specified so that readers can appraise the extent to which this aim was achieved. Examples:
• ‘Because brand names are associated with increased perceived potency [38]’.
• ‘To control for therapist contact and support, expectations, homework tasks, etc, RT [Relax-
ation Techniques] participants were taught a series of relaxation techniques. . . [39]’.
3. What (materials): Describe any physical or informational materials used in the pla-
cebo/sham intervention, including those provided to participants or used in intervention
delivery or in training of intervention providers. Provide information on where the mate-
rials can be accessed (such as an online appendix, URL). Examples:
• ‘We used transcutaneous electrical nerve stimulation (TENS) equipment. . .For sham,
instead of DD [Dense Disperse], a 40Hz adjustable (ADJ) wave was used [40]’.
• ‘. . .placebo (consisting of calcium phosphate, starch, cellulose, and magnesium stearate). . .
the placebo tablets were the same size and shape as the penicillin tablets, the tablets were not
identical owing to the cost implications of overencapsulation (the placebo tablets were
unmarked, and the penicillin tablets were marked) [41]’.
4. What (procedures): Describe each of the procedures, activities, and/or processes used
in the placebo/sham intervention, including any enabling or support activities. Beyond
describing standard procedures, reporting of more subtle procedures (such as nonverbal cues)
[42, 43] and context [44] can influence outcomes. Examples:
Table 2. (Continued)
Item Where Located Where Located
Primary paper
(page or
appendix
number)
Other
(details)
Primary paper
(page or
appendix
number)
Other
(details)
Active intervention Placebo/sham intervention
11 How well: planned
Planned: If intervention adherence or fidelity
was assessed, describe how and by whom, and if
any strategies were used to maintain or improve
fidelity, describe them
Planned: If placebo/sham intervention adherence or
fidelity was assessed, describe how and by whom,
and if any strategies were used to maintain or
improve fidelity, describe them
12 How well: actual
Actual: If intervention adherence or fidelity was
assessed, describe the extent to which the
intervention was delivered as planned
Actual: If placebo/sham intervention adherence or
fidelity was assessed, describe the extent to which
the intervention was delivered as planned
13 Measuring the success of blinding
Was blinding measured, and if so, how, and
what were the results of such measurement?
https://doi.org/10.1371/journal.pmed.1003294.t002
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• ‘Participants were encouraged to discuss their health anxiety and helpful ways of coping with
it and to provide support to others randomised to the control group. The discussion forum
was monitored by a clinical psychologist on a daily basis to ensure that discussions were con-
ducted in a respectful manner [45]’.
• ‘The placebo group received a sham Kinesio Tape application, consisting of a single I-strip of
the same tape applied transversely immediately above the point of maximum lumbar pain
[46]’.
5. Who provided: For each category of placebo/sham intervention provider (such as
psychologist, nursing assistant), describe their expertise, background, and any specific
training given. [47] Examples:
• ‘4 physical therapists, all with a minimum of 5 years of clinical experience in outpatient
orthopaedic settings [48]’.
• ‘Six acupuncturists trained in traditional Chinese medicine, licensed by the Texas State
Board of Medical Examiners, were recruited through the American College of Acupuncture
& Oriental Medicine (ACAOM). To ensure uniformity, all were Chinese, male, and had at
least two years of clinical experience [40]’.
6. How: Describe the modes of delivery (such as face to face or by some other mecha-
nism, such as internet or telephone) of the placebo/sham intervention and whether it was
provided individually or in a group. Examples:
• ‘Three of the sessions were face-to-face, where the patient came into the hospital to meet
with the therapist. The other five sessions were completed by telephone to increase the likeli-
hood of attendance and reduce the stress of travel for participants [39]’.
• ‘Intervention was delivered over the phone [49]’.
7. Where: Describe the type(s) of locations(s) and settings where the placebo/sham
intervention occurred, including any necessary infrastructure or relevant features. Both
geographic location and features of the location (setting) can be important. Examples:
• ‘32 hospital sites in the UK [50]’.
• ‘Cadet Physical Therapy Clinic at the United States Military Academy or Keller Army Com-
munity Hospital at West Point, NY [48]’.
8. When and how much: Describe the number of times the placebo/sham intervention
was delivered and over what period of time, including the number of sessions, their sched-
ule, and their duration, intensity, or dose. If relevant, include the duration of the pre- and
postrandomisation consultations. Reporting the pre- and postintervention consultation details
is especially important in cases in which practitioners are not blinded after randomisation (as
is often the case in sham surgery trials). In the prerandomisation consultation, equal time and
the same ‘quality of care’ [51] might be spent describing the placebo compared with the experi-
mental active intervention. One of our surgical trial experts (JLR) highlighted his experience of
the ease with which postsurgical consultations or clinical contact with other treating health
professionals can advertently or inadvertently unblind the patient and subsequently affect
some clinical outcomes. For example, a recovery nurse might read an operation note (and
learn which group the patient was in) and, not knowing the patient was in a trial, reveal to the
patient which intervention they received. Examples:
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• ‘. . .a loading dose of 1 g of tranexamic acid infused over 10 min, followed by intravenous
infusion of . . .matching placebo (0�9% saline). . .over 8 h [52]’.
• ‘For sham, instead of dense disperse wave, a 40Hz adjustable wave was used. Voltage was
increased until the patient could feel it and then immediately turned off. Patients rested for
20’ with the needles retained, but without TENS stimulation [40]’.
9. Tailoring: If the placebo/sham intervention was planned to be personalised, titrated,
or adapted, then describe what, why, when, and how. Examples:
• ‘Participants were asked if the tape was limiting lumbar movement and, if so, the tape was
reapplied so that they had unrestricted range of motion [53]’.
• ‘Patients were allowed to receive placebo beyond radiographic progression as long as they
continued to have clinical benefit [54]’.
10. Modifications: If the placebo/sham intervention was modified during the course of
the study, describe the changes (what, why, when, and how). Examples:
• ‘In some cases, the face-to-face were replaced with phone sessions if needed [55]’.
• ‘. . .the protocol was amended to require a time-out before the beginning of surgery [sham
neurosurgery] on each side of the brain, with the coordinates confirmed by the surgeon and
documented in writing by a study coordinator or other surgical team member before pene-
tration of the brain [56]’.
11. How well (planned): If placebo/sham intervention adherence or fidelity was
assessed, describe how and by whom, and if any strategies were used to maintain or
improve fidelity, describe them. Planning to measure adherence to active as well as placebo/
sham intervention could help detect whether an adverse event or unblinding may have con-
tributed to change in adherence. Examples:
• ‘We also requested that patients complete a diary card on which the number of pills [placebo
and active intervention] taken every day was recorded [57]’.
• ‘[Sham exercise] Sessions were recorded in a logbook to ensure compliance [58]’.
12. How well (actual): If placebo/sham intervention adherence or fidelity was assessed,
describe the extent to which the intervention was delivered as planned. Examples:
• ‘Four patients did not receive the allocated injection (1 in the placebo group and 3 in the cor-
ticosteroid group) due to nonattendance (n = 2; 1%) or alternative medical advice (n = 2;
1%) [59]’.
• ‘. . .the proportion of patients who reported taking at least 75% of the tablets was similar in
the two groups (79% in the penicillin group and 78% in the placebo group) [41]’.
13. Measuring the success of blinding: Was blinding measured, and if so, how, and what
were the results of such measurement? Failure to demonstrate the success of blinding does
not imply that the trial is invalid or lower quality. However, it can be useful to know whether
blinding was successful in cases where it was measured. Examples:
• ‘As the James’ blinding indices were>0.5 and Bang’s blinding indices did not approach 1 or
−1, participants were considered to have been blinded successfully on average [60]’.
• ‘Treatment allocation was correctly guessed by the outcome assessor in 53% (20/38) of cases
receiving the placebo injection only, 39% (16/41) of cases receiving the placebo injection
PLOS MEDICINE
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003294 September 21, 2020 10 / 15
plus physiotherapy, 44% (18/41) of cases receiving the corticosteroid injection only, and 39%
(15/38) of cases receiving the corticosteroid injection plus physiotherapy [59]’.
Discussion
Summary
To facilitate critical appraisal of the benefits and harms of the active interventions with which
they are compared, placebo or sham controls need to be reported with the same rigour as
experimental active interventions. Some features of placebo or sham controls require emphasis
for complete reporting, such as nonverbal cues, setting, and success of blinding. Here, we
report the development of TIDieR-Placebo, a reporting guideline intended to encourage the
concise and accurate reporting of the nature and implementation of placebo or sham controls
so as to aid in the interpretation and use of clinical research findings.
Strengths and limitations
We followed the methodology recommended by the EQUATOR Network and believe this is
the first guideline to explicitly incorporate patient perspectives. A limitation is that our survey
for eliciting potential TIDieR-Placebo items asked readers to consider drug, surgery, psycho-
logical, and acupuncture, but not some other intervention subtypes such as physiotherapy,
psychological, or behavioural interventions. To mitigate this, some members of the team are
behavioural trial (CM) and physiotherapy trial (SL) experts. Also, our sample of survey respon-
dents, whilst experts in placebo/sham interventions, may have been unrepresentative. Because
our background research showed that placebo components are often ignored, we believed it
was necessary to focus on researchers who were familiar with placebo and sham interventions.
To mitigate this, we sent the manuscript to 20 trialists who user tested the manuscript and
took their feedback into account.
Conclusion and recommendations
TIDieR-Placebo is a user-friendly guide for reporting placebo and sham control interventions
that can be used alongside other checklists. Its use will enhance the understanding and ability
to implement and appraise placebo- and sham-controlled trials. We would encourage that it
be recommended by journal editors, included by the EQUATOR Network, and used alongside
other checklists, particularly CONSORT. Core members of the panel will work with EQUA-
TOR, CONSORT, and TIDieR working groups to review and develop the guideline in the
future.
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